ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

Senate Votes To Kill A 10% Cut For NIH; Less Severe Budget Cuts Still Possible

May 26, 1995

Opdivo Study Shows 41 Percent One-Year Survival In Patients With at Least Two Past Therapies

November 28, 2014

ACCC To Present Program On Impact Of New Technology

January 23, 1981

NCI Outlines Plan for Marin County Breast Cancer Review

November 22, 2002

ACS Prostate Cancer Recommendations Move Forward

August 7, 1992

Rhoads Suggests Plan For 200 Clinical Centers

January 28, 1977